Oncolytics Biotech (ONCY) Q4 2025 earnings summary

Executive summary

• Clinical-stage biopharma focused on pelareorep, an intravenously delivered immunotherapy targeting RAS-mutated tumors, with ongoing trials in GI cancers, metastatic colorectal cancer, anal cancer, and pancreatic cancer.

• Pelareorep has shown promising efficacy and safety in multiple clinical studies, including improved response rates and survival in difficult-to-treat cancers.

• The company has not achieved profitability, continues to incur substantial losses, and faces substantial doubt about its ability to continue as a going concern without additional financing.

• Management is pursuing strategic partnerships and additional capital to advance clinical programs and achieve regulatory milestones.

Financial highlights

• Net loss for 2025 was $28.8 million, compared to $22.8 million in 2024.

• Research and development expenses decreased to $13.3 million (from $15.4 million in 2024), mainly due to lower clinical trial and manufacturing costs.

• General and administrative expenses increased to $15.4 million (from $10.1 million in 2024), driven by higher professional fees, transaction costs, and stock-based compensation.

• Cash and cash equivalents at year-end 2025 were $5.2 million, down from $11.1 million at year-end 2024.

• Raised $14.1 million in net proceeds from equity offerings and SEPA arrangement in 2025.

Outlook and guidance

• Current cash resources are insufficient to fund planned operations over the next 12 months; additional capital is required.

• Focus remains on advancing pelareorep in GI cancers, with new Phase 2 and potential registrational studies planned for 2026.

• Strategic partnerships and further equity financing are being pursued to support ongoing and future clinical trials.